---
title: Scores Parkinson movement from video
nct_id: NCT07381751
status: RECRUITING
sponsor: Hong Kong University of Science and Technology
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07381751"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07381751"
last_fetched: "2026-07-08T14:01:19.144Z"
source: "Parkinson's Pathways (curated)"
---
# Scores Parkinson movement from video

**Goal (in five words):** Scores Parkinson movement from video

**Official Title:** Artificial Intelligence-assisted MDS-UPDRS Assessment for Parkinson's Disease

**Trial ID:** [NCT07381751](https://clinicaltrials.gov/study/NCT07381751)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Hong Kong University of Science and Technology
- **Target Enrollment:** 500 participants
- **Start Date:** 2026-06-01
- **Completion Date:** 2029-02-28
- **Conditions:** Parkinson Disease
- **Interventions:** Observational
- **Intervention Types:** OTHER

## Summary For Families

The goal is to create and test an artificial intelligence tool that can score the standard Parkinson's motor exam (MDS-UPDRS Part III) from ordinary color video, so scoring is less subjective and easier to use outside specialized clinics. Participants will have the usual clinician-rated motor exam while being filmed with synchronized color and depth video, and those videos will be processed by a deep learning system that estimates the same scores. The AI results will be compared, with reviewers blinded, against the clinicians' ratings using agreement and sensitivity analyses to see how well the tool matches human raters and detects change. The study plans to recruit about 500 adults aged 18 to 95 with clinically established Parkinson's disease from Queen Elizabeth Hospital in Hong Kong who can give consent and be video-recorded, excluding people with major vision, hearing, or musculoskeletal problems or other serious neurologic or systemic conditions that would affect the assessment.

## What This Actually Involves

**Placebo** _(From the protocol)_: This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(Ask the coordinator)_: Ask the coordinator what tests and procedures are involved, for example blood draws, scans, or questionnaires, and whether any are uncomfortable or invasive.

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 95 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Age ≥18 years
2. Diagnosis of "Clinically Established PD" as defined by the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (MDS-PD criteria) \[12\]
3. Able to provide informed consent and willing to participate in video-recorded MDS-UPDRS Part III assessments
4. No significant visual, auditory, or musculoskeletal impairments that would interfere with video-based motor assessments

Exclusion Criteria:

1. Unwillingness to be video recorded for study purposes
2. History of neurodevelopmental disorder, neurodegenerative disease other than PD, CNS infection, neuroinflammatory disease (e.g. multiple sclerosis, CNS lupus), malignancy within the last 10 years, cerebrovascular accident, HIV infection, systemic autoimmune disease, alcohol dependence or other substance use
```

## Locations (2)

- Hong Kong University of Science and Technology, Hong Kong, China _(22.2783, 114.1747)_
  - Qian Zhang, PhD, (CONTACT), +852-23588766, qianzh@ust.hk
  - Hiu Yi Wong, PhD, (CONTACT), +852-23587344, annawong@ust.hk
  - Qian Zhang, PhD, (PRINCIPAL_INVESTIGATOR)
- Queen Elizabeth Hospital, Hong Kong, Hong Kong _(22.2783, 114.1747)_
  - Qian Zhang, PhD, (CONTACT), +852 2358 8766, qianzh@cse.ust.hk

## Central Contacts

- Qian Zhang, PhD, (CONTACT), +852-23588766, qianzh@ust.hk
- Hiu Yi Wong, PhD, (CONTACT), +852-23587344, annawong@ust.hk

---

*Canonical: https://parkinsonspathways.com/trial/NCT07381751*  
*HTML version: https://parkinsonspathways.com/trial/NCT07381751*  
*Source data: https://clinicaltrials.gov/study/NCT07381751*